RecruitingMultiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants with relapsed/refractory multiple myeloma. The names of the study drugs involved in this study are: * DC/MM fusion vaccine (a type of personalized cancer vaccine) * Granulocyte-macrophage colony-stimulating factor (GM-CSF) (a type of growth factor or hormone)
Sponsor: David Avigan
You may qualify if…
- ✓ Patients must be eligible to receive standard of care CAR T-cell therapy for relapsed or refractory multiple myeloma
- ✓ Patients must be ≥18 years of age
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- ✓ Patients must have 20% or more plasma cells in the bone marrow core or aspirate differential within 30 days prior to enrollment.
- ✓ Patients must have adequate organ function as defined below:
- ✓ Total bilirubin ≤ 1.5 x institutional upper limit of normal
- ✓ AST ≤ 3 x institutional upper limit of normal
- ✓ ALT ≤ 3 x institutional upper limit of normal
You may not qualify if…
- ✕ Patients receiving other investigational drugs
- ✕ Patients with Plasma Cell Leukemia
- ✕ Patients who have known active uncontrolled infections with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)
- ✕ Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias. Prior to study entry, any ECG abnormality at screening will be documented by the investigator as not medically relevant.
- ✕ Female patients who are pregnant (positive β-HCG) or breastfeeding.
- ✕ Prior organ transplant requiring immunosuppressive therapy.
- ✕ Uncontrolled intercurrent illness including, but not limited to: active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.
- ✕ History of intolerance to CAR-T related drugs or GM-CSF.
Where it's recruiting
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT07377435 · last updated 2026-05-08